Collateral damage: the conundrum of drug safety

被引:0
作者
E. A. M. Gale
机构
[1] Southmead Hospital,Diabetes and Metabolism, Medical School Unit
来源
Diabetologia | 2009年 / 52卷
关键词
Diabetes; Diabetes therapies; Drug safety; Exenatide; Pharmacovigilance;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1975 / 1982
页数:7
相关论文
共 50 条
[1]  
Smith U(2009)Does diabetes therapy influence the risk of cancer? Diabetologia 52 1699-1708
[2]  
Gale EAM(2007)Effect of rosiglitazone on the risk of myocardial infarction N Engl J Med 356 2457-2471
[3]  
Nissen SE(2007)Finding new treatments for diabetes—how many, how fast, how good? N Engl J Med 356 437-440
[4]  
Wolski K(2006)The market in diabetes Diabetologia 49 247-252
[5]  
Nathan DM(2009)Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 52 17-30
[6]  
Hauber A(2004)The Hawthorne Studies: a fable for our times? QJM 97 439-449
[7]  
Gale EAM(2007)Recruitment to a clinical trial improves glycemic control in patients with diabetes Diabetes Care 30 2989-2992
[8]  
Nathan DM(2000)A drug on the market? Lancet 355 61-63
[9]  
Buse JB(2004)Detection, verification and quantification of adverse drug reactions BMJ 329 44-47
[10]  
Davidson MB(1998)Time to act on drug safety JAMA 279 1571-1573